MAVORIXAFOR

Search structure
Synonyms:
Status: Phase 3
Entry Type: Small molecule
Molecule Category: UKNOWN
UNII: 0G9LGB5O2W

Structure
InChI Key WVLHHLRVNDMIAR-IBGZPJMESA-N
Smile NCCCCN(Cc1nc2ccccc2[nH]1)[C@H]1CCCc2cccnc21
InChI
InChI=1S/C21H27N5/c22-12-3-4-14-26(15-20-24-17-9-1-2-10-18(17)25-20)19-11-5-7-16-8-6-13-23-21(16)19/h1-2,6,8-10,13,19H,3-5,7,11-12,14-15,22H2,(H,24,25)/t19-/m0/s1

Physicochemical Descriptors

Property Name Value
Molecular Formula C21H27N5
Molecular Weight 349.48
AlogP 3.58
Hydrogen Bond Acceptor 4.0
Hydrogen Bond Donor 2.0
Number of Rotational Bond 7.0
Polar Surface Area 70.83
Molecular species BASE
Aromatic Rings 3.0
Heavy Atoms 26.0

Pharmacology

Action Mechanism of Action Reference
ANTAGONIST C-X-C chemokine receptor type 4 antagonist PubMed PubMed PubMed
Targets EC50(nM) IC50(nM) Kd(nM) Ki(nM) Inhibition(%)
Enzyme Cytochrome P450 Cytochrome P450 family 2 Cytochrome P450 family 2C Cytochrome P450 2C19
- - - - 20
Enzyme Cytochrome P450 Cytochrome P450 family 2 Cytochrome P450 family 2D Cytochrome P450 2D6
- 1600-1640 - - 100
Enzyme Cytochrome P450 Cytochrome P450 family 3 Cytochrome P450 family 3A Cytochrome P450 3A4
- - - - 35
Membrane receptor Family A G protein-coupled receptor Peptide receptor (family A GPCR) Chemokine receptor CXC chemokine receptor
- 5-30 - - -

Indications

Mesh Heading Maximum Phase Mesh ID Reference
Carcinoma, Renal Cell 1 D002292 ClinicalTrials
Melanoma 1 D008545 ClinicalTrials
HIV Infections 1 D015658 ClinicalTrials
Waldenstrom Macroglobulinemia 1 D008258 ClinicalTrials
Neutropenia 1 D009503 ClinicalTrials

Cross References

Resources Reference
ChEBI 138865
ChEMBL CHEMBL518924
DrugBank DB05501
FDA SRS 0G9LGB5O2W
Guide to Pharmacology 8580
SureChEMBL SCHEMBL2511950
ZINC ZINC000033359232
CONTENTS